You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1055 Results
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Oct 2017
Regimen
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    megestrol - oral tablets
May 2019
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
  • medroxyprogesterone
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck which is Platinum Resistant or Refractory
Aug 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Small bowel and appendix
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer
New Drug Funding Program
    Raltitrexed - Adjuvant Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Adjuvant Esophageal, Gastroesophageal Junction, or Gastric Cancer
Jun 2024

Pages